Clinical guidelines, such as the European LeukemiaNet (ELN) and National Comprehensive Cancer Network consensus (NCCN) guidelines, define a FLT3 ITD allelic ratio cutoff of 0.5 as measured by fragment analysis as the optimal risk-stratification criterion in AML [6, 9]. This evidence concerns the gene FLT3 and acute myeloid leukemia.